Adenosine kinase inhibitor design based on pharmacophore modeling

9Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Adenosine kinase (AK) is a ubiquitous intracellular enzyme, which catalyzes the phosphorylation of adenosine (ADO) to adenosine monophosphate (AMP). AK inhibitors have therapeutic potential as analgesic and anti-inflammatory agents. A chemical feature based pharmacophore model has been generated from known AK inhibitors (26 training set compounds) by HypoGen module implemented in CATALYST software. The top ranked hypothesis (Hypo1) contained four features of two hydrogen-bond acceptors (HBA) and two hydrophobic aromatics (Z). Hypo1 was validated by 124 test set molecules with a correlation coefficient of 0.905 between experimental and estimated activity. It was also validated by CatScramble method. Thus, the Hypo1 was exploited for searching new lead compounds over 238,819 chemical compounds in NCI database and then the selected compounds were screened based on restriction estimated activity and Lipinski's rules to evaluate their drug-like properties. Finally we could obtain 72 new lead candidates and the two best compound structures from them were posted.

Cite

CITATION STYLE

APA

Lee, Y., Bharatham, N., Bharatham, K., & Keun, W. L. (2007). Adenosine kinase inhibitor design based on pharmacophore modeling. Bulletin of the Korean Chemical Society, 28(4), 561–566. https://doi.org/10.5012/bkcs.2007.28.4.561

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free